nivolumab,ipilimumab,sunitinib,pazopanib
bms,pfizer,association pour la recherche des thérapeutiques innovantes en cancérologie,novartis
['ipilimumab', 'nivo', 'nivolumab', 'bionikk', 'rcc,(-irccs),(-srcc),(-urcc)']
in-situ immune markers predict nivolumab +/- ipilimumab efficacy in frontline mccrcc: key ancillary analyses from the #bionikk randomized trial. presented by . #esmo22 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology